The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EORTC CLTF 2021 | Mechanism of CXCR4 inhibition
Lilach Moyal, PhD, Tel Aviv University, Tel Aviv, Israel, explains how inhibition of the CXCR4/CXCL12 axis leads to tumor cell death. CXCR4 antagonists bind to the CXCR4 receptor and prevent CXCL12 from inducing signaling cascades resulting in chemotaxis and survival of malignant cells, which eventually results in their apoptosis. This interview took place at the EORTC Cutaneous Lymphoma Group 20-21 meeting in Marseille.
